Par Drugs And Chemicals Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026, following a board meeting held on May 14, 2026. The company reported a total income of ₹331.13 million for the final quarter of FY26, representing an 8.0% increase compared to ₹306.68 million in the previous quarter (Q3 FY26). On a year-on-year basis, revenue saw a marginal growth of approximately 1.1% from ₹327.46 million in the corresponding quarter of the previous year (Q4 FY25). Net profit for the current quarter stood at ₹41.45 million, showing a robust growth of 176.3% from ₹15.00 million in the previous quarter and a 14.2% increase from ₹36.30 million in the same period last year.

Par Drugs And Chemicals Limited, established in 1999 and headquartered in Vadodara, Gujarat, is a specialist manufacturer of Active Pharmaceutical Ingredients (APIs) and fine chemicals. The company is a leading producer in the antacid molecules segment, with a diverse portfolio that includes 18 APIs and 10 fine chemicals, such as Magnesium Hydroxide and Aluminium Hydroxide. Operating primarily from its manufacturing facilities in Bhavnagar, the company serves both domestic and international markets. As of early 2026, the company maintains a strong promoter holding of 73.41%, with no significant holdings by domestic or foreign institutional investors reported in the latest shareholding patterns.